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Background: An increasing number of autoantibodies are being described in epilepsy and other seizure-related
disorders. A pathogenic role of autoantibodies in epilepsy has been suggested based on observations of the efﬁ-
cacy of immunotherapy.
Objective: This study aimed to report a new case of autoimmune-mediated encephalopathy and seizures caused
by autoantibodies to voltage-gated potassium channels (VGKCs) and voltage-gated calcium channels (VGCCs)
(P/Q-type) and the response to immunotherapy.
Design: This study follows a case report design.
Setting: This study was conducted in a tertiary care center.
Patients: Our patient was an eighteen-year-old female with new-onset encephalopathy and refractory seizures.
Intervention:Our patient was treated for ﬁve dayswith intravenousmethylprednisolone (IVMP) and intravenous
immunoglobulin (IVIG).
Results:After treatmentwith IVMP and IVIG, our patient showed signiﬁcant clinical improvement and did not ex-
hibit any seizures during the one-month follow-up period.
Conclusions: Here, we report a rare case of an autoimmune encephalopathy and seizures associated with the
presence of two surface neuronal autoantibodies. This report highlights the importance of early diagnosis of au-
toimmune epilepsy, as early immunomodulating treatments improve the outcome.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Many central nervous system (CNS) disorders characterized by the
production of autoantibodies that are directed against cell-surface pro-
teins result in early and prominent seizures that are commonly refracto-
ry to conventional antiepileptic drugs (AEDs) but often have a good
response to immunotherapies [1].
2. Case report
An 18-year-old, right-handed female was healthy until 6 weeks
prior to observation when she developed new-onset seizures without
a clear provocative cause. The seizures started with well-formed visual
hallucinations consisting of an aura of seeing strange men entering the
room and trying to attack and rape her, followed by vocalization and
severe facial grimacing to the right with posturing of both arms with
loss of awareness with or without secondary generalization; the sei-
zures were recurrent, arriving in clusters, and not responding to AEDs.
Her family had noted a personality change and episodes of confusion. This is an open access article under2 weeks prior to the ﬁrst seizure; it is not clear whether the patient
had nonconvulsive status epilepticus or not during those episodes. Her
examinations on admission were notable for waxing and waning of
confusion and difﬁculty following complex commands. Four weeks
after seizure onset, the patient developed status epilepticus and re-
quired intensive care unit (ICU) admission and mechanical ventilation.
The cerebrospinal ﬂuid (CSF) revealed 2 white cells/mm [3] with nor-
mal CSF protein and glucose levels, and oligoclonal bands were not
seen in the CSF or serum. Blood cultures were sterile. Routine blood
and inﬂammatory markers, including serum C reactive protein, were
normal except for hyponatremia (sodium, 122 mEq/L). Antibodies
against thyroperoxidase (TPO) and thyroglobulin were negative.
Antinuclear antibodies (ANA), anti-ds DNA, and anti-SSA and anti-SSB
were negative. Brain imaging (CT and MRI) was normal postrecovery
from status epilepticus (Figs. A–F). During ICU admission, the patient
was connected to a continuous video-electroencephalogram (cEEG)
that demonstrated a generalized slow background activity interictally
(~4.5 Hz). Five seizures were recorded, all without motor activity,
starting in the left occipitoparietal region and spreading to the left
hemisphere with secondary generalization. The patient was treated
for 5 days with intravenous corticosteroids followed by intravenous
immunoglobulin (IVIG). The patient improved signiﬁcantly afterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Figs. A–B.Magnetic resonance imaging (MRI) during status epilepticus shows ictal-related changes. Axial FLAIR and T2-weighted images show hyperintensity involving the cortex of left
temporal lobe and left thalamus.
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tion. She was transferred to the neurology ward, and her examinations
showed normal higher mental functions without recurrence of seizures
over the one-month follow-up period.
Serum autoantibodies were tested by Mayo Medical Laboratories at
theMayo Clinic (Rochester, Minnesota). The test identiﬁed the presence
of two antibodies against voltage-gated potassium channels (VGKCs)
and voltage-gated calcium channels (VGCCs) (P/Q-type).
N-methyl-D-aspartate receptor (NMDA-R) antibodies were not
detected.
An extensiveworkup to exclude theneoplastic processwas conduct-
ed, and imaging using CT, including the chest–abdomen–pelvis, did not
reveal any ﬁndings. A PET study showed focal intense activity anterior
to the esophagus that was worrisome. Further follow-up for this hot
spot was stopped because of guardian refusal.
3. Comment
We have described a case of autoimmune encephalopathy and re-
fractory seizures with the presence of two autoantibodies to neuronal
cell-surface proteins. The encephalitides associated with antibodiesFigs. C–D. Axial DWI and ADCmap images show restriction diffusion indicated by bright signalagainst cell-surface antigens differ from those related to intracellular
antigens in several important respects. First, the cell-surface target
antigens are disrupted by the antibodies. Second, the association with
malignancy is much less consistent. Third, symptoms can more com-
monly be reversed with treatment. Finally, the symptoms relate to the
disruption of the target antigen [2]. Immune-mediated encephalitides
resulting in seizures and status epilepticus are becoming increasingly
recognized [3]. Newly identiﬁed autoantibody speciﬁcities that strongly
correlate with clinical seizures include N-methyl-D-aspartate (NMDA)
[4], γ-aminobutyric acid B (GABA B receptor) [5], and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [6]. The
accumulated data support an autoimmune basis in some patients with
AED-resistant seizures [7], including those lacking a typical “limbic
encephalitis” phenotype [1,8], and seizures can be the onlymanifestation
without other recognized clinical accompaniments of limbic encephalitis
[9].
The diagnosis of autoimmune epilepsy requires a high index of
suspicion, and the clues for diagnosis include an unusually high sei-
zure frequency, intraindividual seizure variability or multifocality, AED
resistance, and a personal or a family history of autoimmunity [9].
Hyponatremia provides another diagnostic clue favoring an autoimmuneon the DWI and dark signal on the ADCmap corresponding to the same areas in Figs. A–B.
Figs. E–F.MRI image postrecovery from status epilepticus. Axial FLAIR and DWI show resolution of previously seen abnormalities. ADC map and T2-weighted images (not shown) also
were normal.
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with VGKC autoantibody-associated encephalopathy, reﬂecting a
possible autoimmune hypothalamitis.
Antibodies that bind to the VGKC complex were initially described
in patients with peripheral nerve hyperexcitability (neuromyotonia),
encephalitis, Morvan syndrome, and various other disorders [11,12].
Very recent experiments have demonstrated thatmost of the antibodies
in the serum of patients with these disorders do not bind directly
to VGKCs. Instead, the serum of patients with limbic encephalitis and
VGKC-speciﬁc antibodies is most often directed against LGI1 leucine-
rich glioma-inactivated protein 1, a secreted protein that interacts
with several transmembrane synaptic proteins to form a protein com-
plex. Leucine-rich glioma-inactivated-speciﬁc antibodies are associated
with limbic encephalitis, several types of seizures, and frequent
hyponatremia. Mutations of LGI1 are associated with epilepsy [13]. The
disorder is rarely paraneoplastic, and the response to treatment is
often promising [14,15]. Voltage-gated calcium channel-speciﬁc anti-
bodies are strongly associated with Lambert–Eaton myasthenic syn-
drome, a neuromuscular disorder that typically causes proximal
weakness and autonomic symptoms. These symptoms are attributed
to the autoimmune disruption of neuromuscular transmission by anti-
bodies speciﬁc for P/Q-type VGCCs [16]. Patients with VGCC antibodies
may develop a cerebellar syndromewith or without the neuromuscular
junction disorder [17]. The presence of VGCC-speciﬁc antibodies can
also occur in patients with other paraneoplastic neurological disorders
or in patients with cancer who do not have a neurological syndrome
[18]. In a study of patients with long-standing epilepsy, VGCC-speciﬁc
antibodies were found in only one patient. Therefore, it is difﬁcult to as-
certain whether VGCC-speciﬁc antibodies have a direct pathogenic role
in epilepsy or simply coexist with epilepsy.
Early immunotherapy will most likely improve the eventual out-
comes. In a recent study, all patients exhibiting VGKC-seropositive sei-
zure disorder were responsive to immunotherapy.
Whether the presence of the two surface neuronal autoantibodies
had any special effects in this case is difﬁcult to determine, as the num-
ber of cases of general autoimmune encephalitis is limited; however,
the accumulation of more data with further clinical and paraclinical
data may answer this question.
We conclude that an evaluation for the diagnosis of autoimmune ep-
ilepsy is critical in patients who presentwith the appropriate diagnostic
clues and that immunotherapy should be started as early as possible.Author contributions
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